Confirmation of extended-spectrum β-lactamase-producing Serratia marcescens: Preliminary report from Taiwan

Wen Liang Yu, Lii Tzu Wu, Michael A. Pfaller, Patricia L. Winokur, Ronald N. Jones

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Although Serratia marcescens is a common cause of nosocomial infection in Taiwan, strains producing extended-spectrum β-lactamases (ESBLs) are rare. We detected four clinical isolates of S. marcescens from Taiwan that exhibited resistance to cefotaxime (MICs, > 256 μg/ml) and cefepime (MICs, ≥ 32 μg/ml), but were susceptible to imipenem and meropenem. Transconjugants revealed similar MIC profiles when compared to the parental strains. Isoelectric focusing revealed one major transferable β-lactamase (pI 8.4), which was further identified as CTX-M-3 by polymerase chain reaction and gene sequencing. An AmpC-like enzyme (pI 8.8) was not transferable. All four isolates had significant MIC reductions of ≥3 log 2 dilutions for cefepime in the presence of clavulanic acid, compatible with the presence of an ESBL (CTX-M-3). Clavulanate did not significantly reduce the cefotaxime MIC for one isolate that may co-produce high-level AmpC β-lactamase (pI 8.8). Since high-level AmpC expression has minimal effect on the activity of cefepime, isolates co-producing AmpC β-lactamase may be recognized as additional ESBL producers by using cefepime as an ESBL screening agent.

Original languageEnglish
Pages (from-to)221-224
Number of pages4
JournalDiagnostic Microbiology and Infectious Disease
Volume45
Issue number4
DOIs
Publication statusPublished - Apr 1 2003
Externally publishedYes

Fingerprint

Serratia marcescens
Taiwan
Clavulanic Acid
Cefotaxime
meropenem
Imipenem
Isoelectric Focusing
Cross Infection
Polymerase Chain Reaction
cefepime
Enzymes
Genes

ASJC Scopus subject areas

  • Infectious Diseases
  • Immunology and Allergy
  • Virology
  • Parasitology
  • Microbiology
  • Immunology
  • Applied Microbiology and Biotechnology

Cite this

Confirmation of extended-spectrum β-lactamase-producing Serratia marcescens : Preliminary report from Taiwan. / Yu, Wen Liang; Wu, Lii Tzu; Pfaller, Michael A.; Winokur, Patricia L.; Jones, Ronald N.

In: Diagnostic Microbiology and Infectious Disease, Vol. 45, No. 4, 01.04.2003, p. 221-224.

Research output: Contribution to journalArticle

Yu, Wen Liang ; Wu, Lii Tzu ; Pfaller, Michael A. ; Winokur, Patricia L. ; Jones, Ronald N. / Confirmation of extended-spectrum β-lactamase-producing Serratia marcescens : Preliminary report from Taiwan. In: Diagnostic Microbiology and Infectious Disease. 2003 ; Vol. 45, No. 4. pp. 221-224.
@article{3b6bd5b3936642bfa54daac601ca8656,
title = "Confirmation of extended-spectrum β-lactamase-producing Serratia marcescens: Preliminary report from Taiwan",
abstract = "Although Serratia marcescens is a common cause of nosocomial infection in Taiwan, strains producing extended-spectrum β-lactamases (ESBLs) are rare. We detected four clinical isolates of S. marcescens from Taiwan that exhibited resistance to cefotaxime (MICs, > 256 μg/ml) and cefepime (MICs, ≥ 32 μg/ml), but were susceptible to imipenem and meropenem. Transconjugants revealed similar MIC profiles when compared to the parental strains. Isoelectric focusing revealed one major transferable β-lactamase (pI 8.4), which was further identified as CTX-M-3 by polymerase chain reaction and gene sequencing. An AmpC-like enzyme (pI 8.8) was not transferable. All four isolates had significant MIC reductions of ≥3 log 2 dilutions for cefepime in the presence of clavulanic acid, compatible with the presence of an ESBL (CTX-M-3). Clavulanate did not significantly reduce the cefotaxime MIC for one isolate that may co-produce high-level AmpC β-lactamase (pI 8.8). Since high-level AmpC expression has minimal effect on the activity of cefepime, isolates co-producing AmpC β-lactamase may be recognized as additional ESBL producers by using cefepime as an ESBL screening agent.",
author = "Yu, {Wen Liang} and Wu, {Lii Tzu} and Pfaller, {Michael A.} and Winokur, {Patricia L.} and Jones, {Ronald N.}",
year = "2003",
month = "4",
day = "1",
doi = "10.1016/S0732-8893(02)00539-4",
language = "English",
volume = "45",
pages = "221--224",
journal = "Diagnostic Microbiology and Infectious Disease",
issn = "0732-8893",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Confirmation of extended-spectrum β-lactamase-producing Serratia marcescens

T2 - Preliminary report from Taiwan

AU - Yu, Wen Liang

AU - Wu, Lii Tzu

AU - Pfaller, Michael A.

AU - Winokur, Patricia L.

AU - Jones, Ronald N.

PY - 2003/4/1

Y1 - 2003/4/1

N2 - Although Serratia marcescens is a common cause of nosocomial infection in Taiwan, strains producing extended-spectrum β-lactamases (ESBLs) are rare. We detected four clinical isolates of S. marcescens from Taiwan that exhibited resistance to cefotaxime (MICs, > 256 μg/ml) and cefepime (MICs, ≥ 32 μg/ml), but were susceptible to imipenem and meropenem. Transconjugants revealed similar MIC profiles when compared to the parental strains. Isoelectric focusing revealed one major transferable β-lactamase (pI 8.4), which was further identified as CTX-M-3 by polymerase chain reaction and gene sequencing. An AmpC-like enzyme (pI 8.8) was not transferable. All four isolates had significant MIC reductions of ≥3 log 2 dilutions for cefepime in the presence of clavulanic acid, compatible with the presence of an ESBL (CTX-M-3). Clavulanate did not significantly reduce the cefotaxime MIC for one isolate that may co-produce high-level AmpC β-lactamase (pI 8.8). Since high-level AmpC expression has minimal effect on the activity of cefepime, isolates co-producing AmpC β-lactamase may be recognized as additional ESBL producers by using cefepime as an ESBL screening agent.

AB - Although Serratia marcescens is a common cause of nosocomial infection in Taiwan, strains producing extended-spectrum β-lactamases (ESBLs) are rare. We detected four clinical isolates of S. marcescens from Taiwan that exhibited resistance to cefotaxime (MICs, > 256 μg/ml) and cefepime (MICs, ≥ 32 μg/ml), but were susceptible to imipenem and meropenem. Transconjugants revealed similar MIC profiles when compared to the parental strains. Isoelectric focusing revealed one major transferable β-lactamase (pI 8.4), which was further identified as CTX-M-3 by polymerase chain reaction and gene sequencing. An AmpC-like enzyme (pI 8.8) was not transferable. All four isolates had significant MIC reductions of ≥3 log 2 dilutions for cefepime in the presence of clavulanic acid, compatible with the presence of an ESBL (CTX-M-3). Clavulanate did not significantly reduce the cefotaxime MIC for one isolate that may co-produce high-level AmpC β-lactamase (pI 8.8). Since high-level AmpC expression has minimal effect on the activity of cefepime, isolates co-producing AmpC β-lactamase may be recognized as additional ESBL producers by using cefepime as an ESBL screening agent.

UR - http://www.scopus.com/inward/record.url?scp=0038025982&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038025982&partnerID=8YFLogxK

U2 - 10.1016/S0732-8893(02)00539-4

DO - 10.1016/S0732-8893(02)00539-4

M3 - Article

C2 - 12729989

AN - SCOPUS:0038025982

VL - 45

SP - 221

EP - 224

JO - Diagnostic Microbiology and Infectious Disease

JF - Diagnostic Microbiology and Infectious Disease

SN - 0732-8893

IS - 4

ER -